Farhang Rabbani, MD
Urology · Newnan, GANPI 1477530897
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,428 of the $1,669 with a category attached, or 85.6%. It is spread thinly across 25 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,078 and has fallen 95.5% since, to $48 in 2025. That places this record below the midpoint for urology clinicians in GA, where the typical reported total is $4,062.
Across 84 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$321
- Novartis$278
- Johnson & Johnson$151
- Amgen$108
- Exelixis Inc.$103
- Bristol Myers Squibb$95
- plus $613 from 19 others
What the payments were for
- Food & beverage$1,42886%
- Education$24114%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 11 | $321 |
| Novartis | 16 | $278 |
| Johnson & Johnson(2 entities) | 6 | $151 |
| Amgen | 6 | $108 |
| Exelixis Inc. | 8 | $103 |
| Bristol Myers Squibb | 6 | $95 |
| Seagen Inc. | 1 | $80 |
| E.r. Squibb & Sons, L.L.C. | 6 | $71 |
| Ambu Inc. | 1 | $51 |
| Merck | 2 | $46 |
| Bayer | 3 | $45 |
| Rochester Medical Corporation | 3 | $43 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| AstraZeneca | 2 | $29 |
| Axonics, Inc. | 1 | $26 |
| Teleflex LLC | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Immunitybio, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Angiodynamics, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Koelis Inc. | 1 | $17 |
| Fortovia Therapeutics, Inc. | 1 | $13 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $11 |
How this compares
$1,669 in reported general payments places this provider in the 30th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 63 | $717 |
| Oxybutynin Chloride | 11 | $196 |
| Ciprofloxacin Hcl | 35 | $119 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $60 |
| Oxycodone Hcl | 14 | $49 |
Paid to pharmacies, not to this prescriber.
Other urology in Newnan
- Micah BlackmonNewnan$15K
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Daniel CanterDecatur$329K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
- James BennettAtlanta$93K
- Anthony BarnesAtlanta$89K
- Scott MillerRoswell$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.